Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.
A histologically-confirmed colorectal tumor
Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.
Patients must not have received cytotoxic chemotherapy previous to enrollment.
You may not be if
Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys
Pregnant or breastfeeding
Any known brain metastases
Non-English speaking patients
Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.
Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.
Clareo Health | Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
